Overnight Health Care: Fauci urges vaccination to protect against Delta variant | White House: ‘Small fraction’ of COVID-19 vaccine doses will be unused
Welcome to Tuesday’s Overnight Healthcare. The incentives being offered to convince people to get vaccinated are getting more creative. Washington State just announced its “Joints for Jabs.” Get vaccinated in a weed dispensary, and you can get a free joint.
Today: Fauci cautions on the spread of the coronavirus variant from India, the White House said unused J&J vaccine doses will be minimal, and a new study showed vaccines led to large declines in COVID-19 hospitalizations and deaths among elderly.
We’ll start with a warning on variants:
COVID-19 variants: Fauci urges vaccination to protect against Delta variant from India
White House chief medical adviser Anthony FauciAnthony FauciFox host claims Fauci lied to Congress, calls for prosecution Fauci, Jill Biden visit New York vaccine site On The Trail: Arizona is microcosm of battle for the GOP MORE said on Tuesday that more than 6 percent of the sequenced COVID-19 infections in the U.S. trace to the highly transmissible Delta variant that was first found in India.
The Delta variant, known by the scientific name B.1.617.2, has spread from where it was first discovered in India to 60 countries, including the U.K., where it has become the dominant strain making up more than 60 percent of cases.
Fauci warned the Delta variant is “essentially taking over” the U.K. as its transmissibility “appears to be greater” than the Alpha strain, also known as B.1.1.7, that had been the most prevalent in the country after it was first discovered.
What this means: The Alpha strain, that was originally found in the U.K., became the dominant strain in the U.S. by April, which suggests the Delta strain could follow.
“We cannot let that happen in the United States,” Fauci said during a press briefing, calling on people to get vaccinated, including the second dose, to combat the spread of the variant.
Evidence for second dose: Fauci, who is the director of the National Institute of Allergy and Infectious Diseases (NIAID), said two doses of the Pfizer-BioNTech or AstraZeneca vaccine “appear to be effective” against the Delta variant.
But three weeks after the first dose of the vaccines, both were 33 percent effective against symptomatic infections from the Delta strain.
Pfizer starting test of COVID-19 vaccine in children under 12
Pfizer and BioNTech announced on Tuesday that they will begin to test the effectiveness of their coronavirus vaccine in children younger than 12.
According to Reuters, the companies will conduct a study among nearly 4,500 children across more than 90 clinical sites located in the United States, Poland, Spain and Finland. The study will also follow a specific dosing regimen for certain age groups.
The companies plan to give children between the ages of 5 and 11 a dose of 10 micrograms and children and infants ages 6 months to 5 years a dose of 3 micrograms, the news outlet reported.
In March, Pfizer and BioNTech found their COVID-19 vaccine to be 100 percent effective in children ages 12 to 15. In a clinical trial of 2,260 adolescents, the vaccine was found to generate robust antibody responses.
Maloney presses for action on bill to prevent liability for opioid crisis
Rep. Carolyn MaloneyCarolyn MaloneyHillicon Valley: Biden steps up pressure on Russia to go after cyber criminals | All JBS facilities up and running after ransomware attack | Justice Dept. gives ransomware same priority as terrorism Maloney grills Colonial Pipeline on decision to pay ransom to hackers Hillicon Valley: DC attorney general files antitrust lawsuit against Amazon | DHS to require pipeline companies to report cyberattacks | Activists, parents urge Facebook to drop Instagram for kids plan MORE (D-N.Y.) on Tuesday pressed lawmakers to approve legislation that is meant to prevent the Sackler family from avoiding lawsuits related to the opioid crisis.
“Congress has a duty to ensure that there is accountability for this deadly crisis and to prevent bad actors like the Sacklers from evading responsibility when they harm American communities,” Maloney, who chairs the House Oversight and Reform Committee, told reporters during a press call ahead of a hearing.
“We must pass the SACKLER Act before the bankruptcy plan is confirmed and the Sackler family will practically get off scot-free,” she continued.
Background: The legislation would prevent people who have not filed for bankruptcy from being released from lawsuits brought by states, municipalities or the U.S. government.
Under the current proposal, the Sackler family’s company Purdue Pharma would legally release family members from facing opioid-related lawsuits, while requiring them to pay almost $4.3 billion over 10 years.
During the hearing: Republicans called attention to concerns that drug trafficking at the U.S.-Mexico border is contributing to the opioid crisis in the country.
Ranking member Rep. James ComerJames (Jamie) R. ComerRepublicans seek vindication amid reemergence of Wuhan lab theory Hillicon Valley: DC attorney general files antitrust lawsuit against Amazon | DHS to require pipeline companies to report cyberattacks | Activists, parents urge Facebook to drop Instagram for kids plan Lawmakers request investigation into Postal Service’s covert operations program MORE (R-Ky.) criticized Maloney for not calling a hearing on the “border crisis” and fentanyl trafficking, as demanded by GOP members.
“This hearing misses the point,” he said during his opening statement. “It’s so focused on the Sackler family that it forgets the ongoing epidemic, affecting millions of Americans each day.”
Rep. Rashida TlaibRashida Harbi TlaibHouse candidate in Chicago says gun violence prompted her to run Jewish House Democrats call for Biden to address antisemitism Pavlich: Throwing good money to Iranian terrorism MORE (D-Mich.) responded to the remarks saying the Sackler family was at fault, adding: “It’s not immigrants or China that are drug dealing here.”
White House: ‘Small fraction’ of COVID-19 vaccine doses will be unused
White House officials on Tuesday said they were not concerned about the potential for states to have unused Johnson & Johnson vaccine doses go to waste, adding that the federal government is working on strategies to extend the vaccine’s shelf life.
“Our first goal and our first opportunity is that every dose that’s been ordered by a governor in a state gets used,” White House COVID-19 adviser Andy Slavitt told reporters.
“There is a very very small fraction of doses that have been sent out to states that will ultimately not be used. These will be fractional amounts. And really, will not have any significant bearing on our ability to commit to distribute vaccines globally,” Slavitt said.
Context: Slavitt was responding to a question about Ohio Gov. Mike DeWineMike DeWineWashington state to allow free pot with vaccines Governors can protect civil liberties, too Minnesota offering state fair tickets, fishing licenses to promote coronavirus vaccines MORE (R), who issued an urgent plea Monday evening for vaccine providers to distribute as many doses as possible as quickly as possible.
DeWine said the state has 200,000 doses that will expire by June 23, and he does not have legal options for sending the vaccine elsewhere, either to other states or other countries.
Study: Older Americans saw larger declines in COVID-19 cases, deaths after vaccines became available
Older Americans experienced larger declines in COVID-19 cases, hospitalizations and deaths after the vaccine became available compared to those aged 18 to 49, according to a CDC study.
The study published on Tuesday examined the downward trend in cases, emergency department visits, hospital admissions and deaths among those 65 and older since before the vaccine was authorized in December.
The ratio of cases, emergency department visits, hospital admissions and deaths among those 65 and older compared to 18- to 49-year-olds decreased across the board since the time period when vaccines were not available.
At the same time, a higher portion of the older population, 82 percent, had received at least one dose of a vaccine by May 1, compared to 42 percent of 18- to 49-year-olds.
Conclusions: The CDC concluded that the difference among the age groups shows the effectiveness of the vaccines after the population with a higher rate of vaccinations saw a greater decline in cases, hospitalizations and fatalities.
“From November 29, 2020, to May 1, 2021, COVID-19 incidence, ED visits, hospital admissions, and deaths declined more in older adults, who had higher vaccination coverage, than in younger adults, who had lower coverage,” the study reads.
What we’re reading
What you need to know about the coronavirus variants (The Washington Post)
Member of FDA’s expert panel resigns over controversial Alzheimer’s therapy approval (STAT)
Boeing tested air purifiers like those widely used in schools. It decided not to use them in planes. (Kaiser Health News)
States warn J.&J. doses could expire soon and the White House urges them to consult the F.D.A. (The New York Times)
State by state
Washington announces cannabis giveaway in state-approved ‘joint for jabs’ vaccine campaign (The Washington Post)
Four Oregon businesses issued more than $44,000 in fines for ‘willful’ coronavirus violations (Oregon Live)
COVID-19 cases plunge in Michigan: ‘This 3rd surge … is now officially over’ (Detroit Free Press)
Op-eds in The Hill